Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC

by Vandana Singh, Benzinga Editor

June 18, 2021 7:26 AM | 1 min read | Make a Comment

Cleveland BioLabs Inc CBLI says that the SEC registration statement regarding the previously announced merger with Cytocom Inc was declared effective by the SEC on June 10.
The merger is expected to close in the Q3 of 2021, subject to approval by Cleveland BioLabs' stockholders.
A special meeting of the Cleveland BioLabs stockholders related to the merger will be held virtually on July 6 at 10:00 a.m. E.T.
After the deal's closure, the new combined company will be named Cytocom Inc, and its common stock will trade on NASDAQ under the symbol "CYTO."
The deal was initially announced in October last year, and the registration document was filed in February.
Price Action: CBLI shares are up 8.66% at $5.27 during the premarket trading session on the last check Friday.

Posted In: Biotech M&A News Penny Stocks Health Care General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.